Last reviewed · How we verify
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with moderately high cholesterol.
Details
| Lead sponsor | Aegerion Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 157 |
| Start date | 2007-04 |
| Completion | 2008-10 |
Conditions
- Hypercholesterolemia
Interventions
- Atorvastatin 20 mg
- AEGR-733 5 mg
- AEGR-733 10 mg
- Placebo
- AEGR-733 5 mg + atorvastatin 20 mg
- AEGR-733 10 mg + atorvastatin 20 mg
Primary outcomes
- Percent Change From Baseline in LDL-C at 8 Weeks — Atfer 8 weeks on study drug
Countries
United States